Foresite Capital Management V, LLC
An institutional investment manager in WEST HOLLYWOOD, CA. Its Form 13F for the quarter ended Jun 30, 2026, filed Aug 14, 2026. SEC CIK 1792206.
- Reported value$362.2m
- Positions9
Holdings: 9 positions
The filing on sec.govAs filed, largest first. Reported value is what the manager stated for each position at the quarter end, in US dollars; it is filing data, not a price. Weight is the position's share of the total reported value. Changes compare with the 13F for the quarter ended 2026-03-31.
| Issuer | Class | CUSIP | Reported value$m | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Alumis Inc.ALMS | COM | 022307102 | 166 | 45.8% | 5,896,995 | Unchanged | |
| CG Oncology, Inc.CGON | COM | 156944100 | 76.7 | 21.2% | 1,079,050 | Added+75,000 | |
| Disc Medicine, Inc.IRON | COM | 254604101 | 27.4 | 7.6% | 374,069 | Unchanged | |
| Hims & Hers Health, Inc.HIMS | COM CL A | 433000106 | 25.6 | 7.1% | 738,151 | Unchanged | |
| Pharvaris N.V. | COM | N69605108 | 23.0 | 6.3% | 664,142 | Added+470,017 | |
| Eikon Therapeutics, Inc.EIKN | COM | 282564103 | 17.2 | 4.8% | 1,318,983 | Unchanged | |
| Odyssey Therapeutics, Inc.ODTX | COM | 67613T104 | 13.3 | 3.7% | 713,105 | New+713,105 | |
| Lyell Immunopharma, Inc.LYEL | COM | 55083R203 | 6.7 | 1.8% | 476,386 | Reduced−692 | |
| Nurix Therapeutics, Inc.NRIX | COM | 67080M103 | 6.4 | 1.8% | 265,000 | Unchanged |
Sold out: 1 position
Held at the end of the quarter before and not reported this quarter.
| Issuer | Class | CUSIP | Reported value$ | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Maze Therapeutics, Inc.MAZE | COM | 578784100 | 0.0 | 0.0% | 0 | Sold out−25,905 |
Source: SEC EDGAR, Form 13F-HR, accession 0001104659-26-097121 (on sec.gov). Last ingested by Listed: Oct 22, 2026, 05:26 ET. Listed shows no prices and gives no investment advice.